Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term outcomes with drug-eluting stents versus bare metal stents in the treatment of saphenous vein graft disease (results from the REgistro Regionale AngiopLastiche Emilia-Romagna registry).
Vignali L, Saia F, Manari A, Santarelli A, Rubboli A, Varani E, Piovaccari G, Menozzi A, Percoco G, Benassi A, Rusticali G, Marzaroli P, Guastaroba P, Grilli R, Maresta A, Marzocchi A. Vignali L, et al. Among authors: varani e. Am J Cardiol. 2008 Apr 1;101(7):947-52. doi: 10.1016/j.amjcard.2007.11.055. Epub 2008 Feb 6. Am J Cardiol. 2008. PMID: 18359313 Clinical Trial.
Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting.
Maresta A, Balducelli M, Latini R, Bernardi G, Moccetti T, Sosa C, Barlera S, Varani E, Ribeiro da Silva EE, Monici Preti A, Maggioni AP; STARC II Investigators. Maresta A, et al. Among authors: varani e. Catheter Cardiovasc Interv. 2005 Mar;64(3):375-82. doi: 10.1002/ccd.20290. Catheter Cardiovasc Interv. 2005. PMID: 15736248 Clinical Trial.
Comparison of effectiveness of sirolimus-eluting stents versus bare metal stents for percutaneous coronary intervention in patients at high risk for coronary restenosis or clinical adverse events.
Marzocchi A, Piovaccari G, Manari A, Aurier E, Benassi A, Saia F, Casella G, Varani E, Santarelli A, Guastaroba P, Grilli R, Maresta A. Marzocchi A, et al. Among authors: varani e. Am J Cardiol. 2005 Jun 15;95(12):1409-14. doi: 10.1016/j.amjcard.2005.01.096. Am J Cardiol. 2005. PMID: 15950561
69 results